The PERK pathway inhibitor ISRIB [329] was able to attenuate amyloid β-induced neuronal cell death in AD [330], and was also shown to be promising for therapies targeting ALS [331] and traumatic brain injury (TBI) [332]. This evidence concerns the gene EIF2AK3 and amyotrophic lateral sclerosis.